Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensitive Blood Test Detects Prion Diseases

By LabMedica International staff writers
Posted on 11 Jul 2011
A novel assay has been developed that will rapidly screen blood plasma for variant Creutzfeldt-Jacob disease (vCJD). More...


An integrated antibody-based approach with an improved real-time quaking-induced protein conversion (RT-QuIC) reaction enhanced the detection of vCJD brain tissue diluted into human plasma.

Scientists at the US National Institute of Allergy and Infectious Diseases, (NIAID; Bethesda, MD, USA), collaborated with scientists from Prionics AG, (Schlieren-Zurich, Switzerland), to develop the sensitive bioassay. RT-QuIC, developed only recently, detects the abnormal form of prion protein, which, in purified form, resembles amyloid fibrils. This combined assay, which they call enhanced QuIC (eQuIC), detects approximately 2 attograms (10-18 grams) per mL of proteinase K–resistant prion protein, a 1014-fold dilution, indicating a 10,000-fold increase in sensitivity compared with previously reported methods of vCJD brain tissue detection.

In addition, in early preclinical studies, the eQuIC screening tool has been found to distinguish between plasma and serum samples from scrapie-infected and uninfected hamsters. This rapid and sensitive screening tool that detects prion diseases, also known as transmissible spongiform encephalopathies, would aid in the prevention of prion disease transmission within and between species because animals and people are commonly infected for years before symptoms of the disease appear.

Byron Caughey, PhD, senior investigator in the NIAID Laboratory of Persistent Viral Diseases, said, ""The eQuIC assay in particular provides a practical, high-throughput, and rapid means of testing for amounts of partially protease-resistant form of the host's prion protein that are several orders of magnitude below those typically required to cause prion disease by intracerebral inoculation into animals."

The authors concluded that the remarkable resistance to inactivation of prions relative to other pathogens also makes it important to develop practical assays for prion contamination in a wide variety of materials, such as foods, feeds, transplanted tissues, medical devices, agricultural wastes and by-products, soils, water sources, and other environmental samples. The article was published on May 10, 2011 in the journal mBIO.

Related Links:
US National Institute of Allergy and Infectious Diseases
Prionics AG


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.